Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announces the commercial launch of IRO, a next-generation platform built specifically to overcome the current challenges in CGT manufacturing. The company today revealed the IRO platform at ISCT 2024, International Society for Cell & Gene Therapy’s 30th annual conference, in Vancouver, British Columbia.
Manufacturing remains a critical barrier to scaling cell and gene therapies, limiting the clinical and commercial impact of this life-saving new class of therapies. It is estimated that more than 95% of patients are left without access to cell and gene therapies1. Ori has developed the IRO platform as part of their mission to enable widespread patient access to life-saving cell and gene therapies.
IRO has both the flexibility needed for early process development and the ability to scale into GMP manufacturing with the same instrument, consumables, and process – delivering a seamless transition from R&D to GMP. The IRO platform automates better biology, accelerates therapy development, and enables therapy developers to scale their products’ clinical and commercial impact. By reducing labor by up to 70%, reducing the cost of goods by up to 50%, cutting processing times by up to 25%, and accelerating tech transfer times from months to weeks, IRO could shave years off therapy development timelines, bringing products to patients more quickly.
“A new wave of cell and gene therapies holds immense promise for patients; however, to achieve the true clinical impact, therapies must be not only approvable but also accessible and affordable,” said Jason C. Foster, CEO, Ori Biotech. “Over the last five years, we’ve focused on Biology First, generating best-in-class biological data from over 500 runs with ten different partners, across different cell types and protocols to demonstrate how the IRO platform can Automate Better Biology. For too long, scientists and therapy developers have had to sacrifice biological performance for automation, not anymore.”
SOURCE: GlobeNewswire